The growth of GLP-1 agonist drugs has catapulted their manufacturers into a league of their own in terms of market value: Eli Lilly is the world’s most valuable pharma company with a current market capitalization of around $710bn, while Novo Nordisk is second at around $358bn.
Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean
As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.
More from Outlook
• By
The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.
• By
Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.
• By
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
• By
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.
More from Leadership
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.